On Tuesday, Boehringer Ingelheim announced that it had received approval from the FDA for its medication for patients with COPD.
Cystic fibrosis, a life-threatening disease affecting more than 30,000 patients in the U.S. continues to have limited therapeutic options for treatment. Recently, two advances in treatment include the new PARI eRapid electronic nebulizer system and the potential approval of Orkambi will. They will offer CF patients other options to improve quality of life in both drug delivery and health outcomes. However, the cost may be a significant factor.